Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Status Recruiting

Clinical Trial Summary

This study evaluates the efficacy and safety of second-line treatment of bortezomib in advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive bortezomib while the other half will receive best supporting care.

Clinical Trial Description

There's no standard second-line treatment for advanced intrahepatic cholangiocarcinoma patients.

Previous study indicated high mutation/deletion rate of PTEN gene in intrahepatic cholangiocarcinoma and poor prognosis of those patients with PTEN mutation/deletion. The investigators also found that the activity of proteasomes elevated in cholangiocarcinoma cells with PTEN mutation/deletion.

So the investigators suppose proteasomes inhibitor could improve prognosis of intrahepatic cholangiocarcinoma patients with PTEN mutation/deletion ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03345303
Study type	Interventional
Source	Eastern Hepatobiliary Surgery Hospital
Contact	Yexiong Tan, Ph.D
Phone	00862181875362
Email	yxtan1214@163.COM
Status	Recruiting
Phase	Phase 3
Start date	January 2017
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05678218` - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Active, not recruiting	`NCT03781934` - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations	Phase 1/Phase 2
Completed	`NCT01938729` - Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma	Phase 1
Completed	`NCT03230318` - Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma	Phase 2
Recruiting	`NCT06239532` - HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
Not yet recruiting	`NCT05535647` - Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma	Phase 2
Not yet recruiting	`NCT05009953` - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT02254681` - Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC	Phase 2
Active, not recruiting	`NCT01954745` - A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy	Phase 2
Completed	`NCT01347333` - Stereotactic Body Radiotherapy for Liver Tumors	N/A
Active, not recruiting	`NCT04526106` - REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05285358` - Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases	Phase 1
Completed	`NCT03320980` - RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma	N/A
Withdrawn	`NCT05019677` - GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC	Phase 2
Withdrawn	`NCT03801499` - Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
Completed	`NCT05489692` - HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Recruiting	`NCT06101277` - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)	N/A
Active, not recruiting	`NCT01917370` - VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway	N/A
Withdrawn	`NCT01775280` - Response of Hepatic Tumors to Radioembolization	Phase 2
Not yet recruiting	`NCT05342194` - Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study	Phase 3